Gilead Sciences CEO Daniel O'Day Sells $2.23M in Stock Under Rule 10b5-1 Plan

Insider Trading Summary: Gilead Sciences, Inc. (NASDAQ: GILD)

Executive Overview

On September 1, 2026, Daniel Patrick O'Day, Chairman and Chief Executive Officer of Gilead Sciences, Inc., executed sales totaling 15,000 shares of common stock across three tranches at weighted average prices ranging from $147.51 to $149.38 per share. The cumulative transaction proceeds totaled approximately $2,229,592.04.

Transaction Breakdown

• Tranche 1: 1,600 shares sold at a weighted average price of $147.5087 ($146.94 – $147.92 range).
• Tranche 2: 7,992 shares sold at a weighted average price of $148.3636 ($147.95 – $148.93 range).
• Tranche 3: 5,408 shares sold at a weighted average price of $149.3817 ($148.96 – $149.94 range).

Key Observations

• 10b5-1 Trading Plan: The transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the sales were pre-scheduled and not driven by recent material non-public information.
• Remaining Position: Following these sales, Mr. O'Day directly holds 577,133 shares of Gilead Sciences common stock, retaining a substantial equity stake in the company.